A Study To Evaluate Nmra-335140 Versus Placebo In Participants With Major Depressive Disorder (H-54668)

Nmra-335140-301 (Koastal-1) A Phase 3, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Effects Of Oral Nmra-335140 Versus Placebo In Participants With Major Depressive Disorder 

This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a six-week treatment period (during which participants will receive either NMRA-335140 or placebo). At the completion of the six-week treatment period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).